Cancer Therapy
Combination sorafenib and gemcitabine stabilizes disease in advanced solid tumors
Published in Cancer Weekly, March 7th, 2006
"With its potent inhibitory effects against Raf-1 kinase and vascular endothelial growth factor receptor-2, sorafenib is a novel oral anticancer agent targeting signal transduction and angiogenic pathways. This study is designed to combine sorafenib and gemcitabine due to their compatibility in preclinical models and nonoverlapping clinical toxicities," scientists writing in the journal Clinical Cancer Research report.
L.L. Siu and colleagues, University of Toronto wrote, "An initial dose-escalation part of the study...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-03-07)
More Articles from Cancer Weekly
- Breast Cancer
Fuzzy c-means clustering-based method used to segment breast lesions from MRI - Cancer Diagnostics
CD10 expression used to differentiate trichoepithelioma from basal cell cancer - Lung Cancer
A GSTP1 polymorphism may be linked to survival in advanced non-small cell lung carcinoma - Lymphoma
Phosphatidylinositol-3 kinase/Akt inhibition promoted apoptosis in Hodgkin lymphoma - Prostate Cancer
Expandable endorectal coils used to improve alignment of prostate MR images - Adrenocortical Cancer
Therapeutic strategies for treating adrenocortical carcinoma discussed - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
